Boston Scientific Plummets on Suspension of Defribrillator Sales

Shares of Boston Scientific (NYSE:BSX) are trading 14.6% lower to $6.64 Monday on a report that the medical device company had suspended sales of all implantable cardioverter defibrillators, or ICDs.

According to an analyst note from Bernstein Research, the suspension of sales is due to a documentation error in the company's filings to the Food and Drug Administration regarding a manufacturing process change, which put the company's ICD devices out of compliance with FDA regulations.

A Boston Scientific spokesman declined immediate comment on the matter.

Boston Scientific's ICD business makes up 15% of the company's total revenue, which was $8.2 billion in 2009.